In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

TREAT: Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin) Therapy

Acute Coronary Syndromes (ACS)

John McMurray, FESC
Presenter | see Discussant report Watch the webcast
McMurray, John
(United Kingdom)


Over a median of 29 months, the primary outcome of death or a major cardiovascular event occurred in 632 patients. This presentation will describe the clinical predictors of the primary cardiovascular composite outcome in this extremely high risk population.

The multivariable analyses include standard cardiovascular and diabetes clinical variables (e.g. past CV history, history of diabetes complications e.g. neuropathy), metabolic and renal plasma and urinary biomarkers (e.g. HbA1c, eGFR, urinary albumin creatinine ratio) and novel biomarkers (including high-sensitivity troponin and natriuretic peptides) in this population.

Karl Swedberg, FESC
Discussant | see Presenter abstract Watch the webcast
Swedberg, Karl


711005 - 711006


Clinical Trial Update III
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.